Encapsulated mesalamine granules (Apriso) for ulcerative colitis.

Apriso (Salix) is a new formulation of mesalamine (5-aminosalicylic acid; 5-ASA) approved by the FDA for maintenance of remission in mild to moderate ulcerative colitis (UC). Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease. Various mesalamine formulations have been developed to target drug delivery to areas of the small intestine and colon. Most of these agents require frequent dosing and have a high pill burden. The newest products--Lialda, introduced in 2007, and now Apriso--can be dosed once daily.
JournalThe Medical letter on drugs and therapeutics (Med Lett Drugs Ther) Vol. 51 Issue 1312 Pg. 38-9 (May 18 2009) ISSN: 1523-2859 [Electronic] United States
PMID19448588 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Colitis, Ulcerative (drug therapy)
  • Drug Interactions
  • Humans
  • Mesalamine (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: